title: [Angioimmunoblastic T cell lymphoma: clinical analysis of 42 cases].
abstract: OBJECTIVE
  To explore the clinical characteristics and prognosis of patients with angioimmunoblastic T cell lymphoma (AITL).
  
  
  METHODS
  The clinical features and prognostic factors of 42 cases newly diagnosed as AITL at Peking University Cancer Hospital from January 2007 to August 2012 were retrospectively analyzed.
  
  
  RESULTS
  Their median age was 59(34-76) years. Among them, 97.6% cases (41/42) belonged to Ann Arbor stage III/IV, 73.8% (31/42) cases presented with B symptoms, 85.7% (36/42)cases had painless lymphadenopathy, 52.4% (22/42)cases extranodal involvement, 64.3% (27/42) cases elevated lactate dehydrogenase and 45.2% (19/42) cases elevated β2-microglobulin at diagnosis. And 40.5% (17/42) cases had 3 points of international prognostic index (IPI) score with the highest proportion.First-line chemotherapy was predominantly CHOP (cyclophosphamide, vincristine, doxorubicin, prednisolone) or CHOP-like-based and complete response was achieved in 44.7% (17/38) of them. The median follow-up time was 40 (2-106) months The 1, 2, 5-year survival rates were 78%, 57% and 39% respectively.Statistical analysis showed that IPI was an independent prognostic factor (P = 0.009).Other factors included gender (P = 0.311), age (P = 0.263), with or without B symptoms (P = 0.102), Ki-67 index (P = 0.146) as well as the choice of first-line chemotherapy (P = 0.292) each had a tendency of affecting; the survival rate, but failed to reach statistical significance.
  
  
  CONCLUSIONS
  Angioimmunoblastic T-cell lymphoma is a major type of peripheral T-cell lymphoma. Most AITL patients are elders with a late stage. The disease generally displays an aggressive clinical course and poor prognosis.
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xiao-pei
authors.initials: XP
authors.lastname: Wang
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Zheng
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xie
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Ning-jing
authors.initials: NJ
authors.lastname: Lin
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Ling-yan
authors.initials: LY
authors.lastname: Ping
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Zhi-tao
authors.initials: ZT
authors.lastname: Ying
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Liu
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Deng
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yu-qin
authors.initials: YQ
authors.lastname: Song
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: zhu-jun@bjcancer.org.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies